

9 Feb 2025

## **Submission on the proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD**

Te Kāhui Mātai Arotamariki o Aotearoa | The Paediatric Society of New Zealand (PSNZ) Neurodevelopment Clinical Network appreciates the opportunity to provide feedback on the proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD. Overall, we support the proposal.

We support retaining the limitation that ADHD diagnoses for individuals aged 17 years and younger remain within specialist services. The diagnosis and management of ADHD require specialist skills and expertise in neurodevelopmental conditions and differential diagnosis.

We also support enabling ongoing prescribing and special authority reviews to be undertaken in primary care by a nurse practitioner or general practitioner, provided they receive appropriate training, support, and resources.

Additionally, we encourage consideration of the role of prescribing pharmacists in the ongoing management of ADHD.

Managing ADHD is complex and requires significant time. Ideally, care should be delivered in a multidisciplinary setting to ensure comprehensive support.

Given these factors, with the appropriate support and resourcing, the proposed changes would be beneficial.

Ngā mihi nui,

**Dr Colette Muir**, Co-chair, PSNZ Neurodevelopment Clinical Network, Developmental Paediatrician

**Denise Janes**, Co-Chair, PSNZ Neurodevelopment Clinical Network, Clinical Lead, Physiotherapist

“Tamariki in Aotearoa flourish in health and wellness”